Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 1 · 50%High 0 · 0%

Interferon‐α alone vs interferon‐α plus bevacizumab

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α alone probably leads to lower adverse events (grade ≥ 3) compared with interferon‐α plus bevacizumab (moderate certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 0.77 [0.71, 0.84]
2 studies · 1350 participants
Moderate

Interferon‐α alone vs standard targeted therapies

Adverse events (grade ≥ 3) · previously untreated patients with mRCC

Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).

1 finding from 1 review

Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
RR 1.17 [1.03, 1.32]
1 study · 408 participants
Low